Pneumonia
Conditions
Interventions
Group 1:standard treatment + SR1375 3mg
Group 2:standard treatment + SR1375 10mg
Group 3:standard treatment + placebo
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The subject or his legal representative guardian is willing to participate in the study and sign the informed consent form; 2. Male or female, the age is >= 18 years old; 3. Patients who have been hospitalized or are scheduled to be hospitalized before enrollment during screening; 4. Those who meet the clinical diagnosis of any of the following pneumonia during screening: (1) Moderate or severe COVID-19 infection; (2) Community-acquired pneumonia; (3) Hospital-acquired pneumonia; 5. Female subjects and male subjects whose partners are childbearing potential (WOCBP) must agree to use one or more effective contraceptive methods during the whole study period to 30 days (female) or 90 days (male) after the last dose, and must not donate eggs or sperm; 6. WOCBP and blood ß-HCG of female subjects with natural menopause < 12 months must be negative.
Exclusion criteria
Exclusion criteria: 1. Have serious systemic diseases or clinical issues, are not suitable for participating in the study in the judgement of the investigator; 2. Have diseases that may seriously affect gastrointestinal absorption before screening; 3. Female subjects who are pregnant or lactating; 4. The laboratory test results of the subject are abnormal with clinical significance, and are suitable for participating the trial in the judgement of the investigator; 5. ECG value at screening shows the presence of clinically relevant abnormalities that may affect the safety of the subject or the judgment of the test results; 6. The subject was not suitable for the study in the judgement of the investigator.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| time to the need of high flow oxygen;time to noninvasive mechanical ventilation;time to invasive mechanical ventilation;time to use ECMO;death proportion; | — |
Primary
| Measure | Time frame |
|---|---|
| vital signs;physical examination;hematology;blood biochemistry;coagulation function;arterial blood gas analysis;urine analysis;Blood/urine ß-HCG was test;ECG;Adverse events;Serious Adverse events;concomitant medication;WHO 7 rating scale; | — |
Countries
China
Contacts
Public ContactLi Weimin
West China Hospital, Sichuan University
Outcome results
None listed